Neurotoxicity caused by didanosine on cultured dorsal root ganglion neurons

Cell Biology and Toxicology

Volumn 24, Issue 1, 2008, Pages 113-121

  Liu, H ^a   Liu, Z ^b   Yang, X ^a   Huang, F ^b   Ma, C ^b   Li, Z ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acquired immunodeficiency syndrome; Didanosine; Dorsal root ganglion; Human immunodeficiency virus; Neuropathy

Indexed keywords

DIDANOSINE;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL STRUCTURE; CELL ULTRASTRUCTURE; CLUSTER ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; EMBRYO; LYSOSOME; MICROTUBULE; MITOCHONDRION; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEURITE; NEUROFILAMENT; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SPINAL GANGLION;

ANIMALS; CELL SHAPE; CELLS, CULTURED; DIDANOSINE; GANGLIA, SPINAL; NEURITES; NEURONS; RATS; RATS, WISTAR; TOXICITY TESTS;

HUMAN IMMUNODEFICIENCY VIRUS; RATTUS NORVEGICUS;

EID: 37749009400     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-007-9021-2     Document Type: Article

References (42)

1. Berger JR, Nath A. Remedies for HIV-associated peripheral neuropathy. Neurology 2000;54:2037-8.
2. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
3. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
4. Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, et al. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med 1990;322:1340-5.
5. Cornblath DR, Hoke A. Recent advances in HIV neuropathy. Curr Opin Neurol 2006;19:446-50.
6. Cote HC. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy. Antivir Ther 2005;10 Supplement 2: M3-11.
7. Dalakas M, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′,3′-dideoxycytidine (ddC). Lab Invest 2001;81:1537-44.
8. Ferrari S, Vento S, Monaco S, Cavallaro T, Cainelli F, Rizzuto N, et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc 2006;81:213-9.
9. Gilmer WS. Neurologic problems of the lower extremity associated with HIV and AIDS. Clin Podiatr Med Surg 1998;15:281-303.
10. Hahiguchi K, Bohr VA, de Souza-Pinto NC. Oxidative stress and mitochondrial DNA repair: implications for NRTIs induced DNA damage. Mitochondrion 2004;4:215-22.
11. Hoschele D. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol In Vitro 2006;20:535-46.
12. Hulgan T, Hughes M, Sun X, Smeaton LM, Terry E, Robbins GK, et al. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr 2006;42:450-4.
13. Joseph EK, Chen X, Khasar SG, Levine JD. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 2004;107:147-58.
14. Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006;20:1503-13.
15. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS 2002;16:2105-17.
16. Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003;53:57-64.
17. Keswani SC, Leitz GJ, Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett 2004;371:102-5.
18. Krambovitis E, Porichis F, Spandidos DA. HIV entry inhibitors: a new generation of antiretroviral drugs. Acta Pharmacol Sin 2005;26:1165-73.
19. Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, et al. 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990;322:1333-40.
20. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003;42:14711-9.
21. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 2006;20:675-84.
22. Lopez S, Negredo E, Garrabou G, Puig J, Ruiz L, Sanjurjo E, et al. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses 2006;22:33-9.
23. Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Curr Opin Neurol 2003;16:403-9.
24. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol 2004;157:3-10.
25. Melli G, Keswani SC, Fischer A, Chen W, Hoke A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 2006;129:1330-8.
26. Miro O, Lopez S, Cardellach F, Casademont J. Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings. Antivir Ther 2005;10 Supplement 2: M73-81.
27. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000;22:911-36.
28. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005;10 Supplement 2: M47-52.
29. Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001;6:21-7.
30. Petit F, Fromenty B, Owen A, Estaquier J. Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci 2005;26:258-64.
31. Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006;59:816-24.
32. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta 2006;1757:700-7.
33. Rickert CH, Evers S, Heese C, Reichelt D, Husstedt IW. Immunoglobulin deposition in sural nerves of AIDS patients with distal-symmetric HIV-associated polyneuropathy. Eur J Med Res 2002;7:472-6.
34. Schifitto G, McDermott MP, McArthur JC, Marder K, Sacktor N, Epstein L, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002;58:1764 - 8.
35. Schifitto G, Yiannoutsos CT, Simpson DM, Marra CM, Singer EJ, Kolson DL, et al. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 2006;12:328-31.
36. Simpson DM, Kitch D, Evans SR, McArthur JC, Asmuth DM, Cohen B, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006;66:1679-87.
37. Skopelitis EE, Kokotis PI, Kontos AN, Panayiotakopoulos GD, Konstantinou K, Kordossis T, et al. Distal sensory polyneuropathy in HIV-positive patients in the HAART era: an entity underestimated by clinical examination. Int J STD AIDS 2006;17:467-72.
38. Verma A. Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst 2001;6:8-13.
39. Wulff EA, Simpson DM. Neuromuscular complications of the human immunodeficiency virus type 1 infection. Semin Neurol 1999;19:157-64.
40. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 2000;59:1251-60.
41. Yarchoan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, et al. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526-9.
42. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother 1999;43:121-8.